24 Jul 2025 (48 Days) Date | | - Cons. EPS | - EPS |
27 Jan 2025 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | - EPS |
29 Oct 2024 Date | | - Cons. EPS | - EPS |
28 Oct 2024 Date | | - Cons. EPS | - EPS |
24 Jul 2025 (48 Days) Date | | - Cons. EPS | - EPS |
27 Jan 2025 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | - EPS |
29 Oct 2024 Date | | - Cons. EPS | - EPS |
28 Oct 2024 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Mr. Mark Andrew Upsdell CEO | OTC PINK Exchange | CA75339A1012 ISIN |
CA Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Rapid Dose Therapeutics Corp. is a pioneering life sciences company based in Burlington, Canada, specializing in innovative drug delivery technologies. The company is committed to improving health outcomes by providing advanced solutions for the rapid release of active molecules into the bloodstream. Their target market encompasses the nutraceutical, cannabis healthcare, and pharmaceutical manufacturing industries, for whom they also offer product innovation, production, and consultation services. Through its cutting-edge approach, Rapid Dose Therapeutics aims to enhance the bioavailability of medications, resulting in faster and more efficient drug absorption.